163 related articles for article (PubMed ID: 26425723)
1. FGFR3-TACC3: A novel gene fusion in cervical cancer.
Carneiro BA; Elvin JA; Kamath SD; Ali SM; Paintal AS; Restrepo A; Berry E; Giles FJ; Johnson ML
Gynecol Oncol Rep; 2015 Aug; 13():53-6. PubMed ID: 26425723
[TBL] [Abstract][Full Text] [Related]
2. Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions.
Tamura R; Yoshihara K; Saito T; Ishimura R; Martínez-Ledesma JE; Xin H; Ishiguro T; Mori Y; Yamawaki K; Suda K; Sato S; Itamochi H; Motoyama T; Aoki Y; Okuda S; Casingal CR; Nakaoka H; Inoue I; Verhaak RGW; Komatsu M; Enomoto T
Oncogenesis; 2018 Jan; 7(1):4. PubMed ID: 29358619
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive genomic profiling aids in treatment of a metastatic endometrial cancer.
Dhami J; Hirshfield KM; Ganesan S; Hellmann M; Rojas V; Amorosa JK; Riedlinger GM; Zhong H; Ali SM; Pavlick D; Elvin JA; Rodriguez-Rodriguez L
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29588307
[No Abstract] [Full Text] [Related]
4. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling.
Nelson KN; Meyer AN; Wang CG; Donoghue DJ
Oncotarget; 2018 Sep; 9(76):34306-34319. PubMed ID: 30344944
[TBL] [Abstract][Full Text] [Related]
6. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.
Yuan L; Liu ZH; Lin ZR; Xu LH; Zhong Q; Zeng MS
Cancer Biol Ther; 2014; 15(12):1613-21. PubMed ID: 25535896
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation.
Nelson KN; Meyer AN; Siari A; Campos AR; Motamedchaboki K; Donoghue DJ
Mol Cancer Res; 2016 May; 14(5):458-69. PubMed ID: 26869289
[TBL] [Abstract][Full Text] [Related]
8. Successful Treatment and Retreatment With Erdafitinib for a Patient With
Pham C; Lang D; Iams WT
JTO Clin Res Rep; 2023 May; 4(5):100511. PubMed ID: 37214414
[No Abstract] [Full Text] [Related]
9. FGFR3-TACC3 fusion in solid tumors: mini review.
Costa R; Carneiro BA; Taxter T; Tavora FA; Kalyan A; Pai SA; Chae YK; Giles FJ
Oncotarget; 2016 Aug; 7(34):55924-55938. PubMed ID: 27409839
[TBL] [Abstract][Full Text] [Related]
10. Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic Perspectives.
Picca A; Sansone G; Santonocito OS; Mazzanti CM; Sanson M; Di Stefano AL
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067258
[TBL] [Abstract][Full Text] [Related]
11. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
[TBL] [Abstract][Full Text] [Related]
12. Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples.
Kurobe M; Kojima T; Nishimura K; Kandori S; Kawahara T; Yoshino T; Ueno S; Iizumi Y; Mitsuzuka K; Arai Y; Tsuruta H; Habuchi T; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Kakehi Y; Nagumo Y; Tsutsumi M; Oikawa T; Kikuchi K; Nishiyama H
PLoS One; 2016; 11(12):e0165109. PubMed ID: 27930669
[TBL] [Abstract][Full Text] [Related]
13. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.
Capelletti M; Dodge ME; Ercan D; Hammerman PS; Park SI; Kim J; Sasaki H; Jablons DM; Lipson D; Young L; Stephens PJ; Miller VA; Lindeman NI; Munir KJ; Richards WG; Jänne PA
Clin Cancer Res; 2014 Dec; 20(24):6551-8. PubMed ID: 25294908
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability.
Wang CG; Peiris MN; Meyer AN; Nelson KN; Donoghue DJ
Oncotarget; 2023 Feb; 14():133-145. PubMed ID: 36780330
[TBL] [Abstract][Full Text] [Related]
15. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
[TBL] [Abstract][Full Text] [Related]
16. Varied histomorphology and clinical outcomes of FGFR3-TACC3 fusion gliomas.
McDonald MF; Athukuri P; Anand A; Gopakumar S; Jalali A; Patel AJ; Rao G; Goodman JC; Lu HC; Mandel JJ
Neurosurg Focus; 2022 Dec; 53(6):E16. PubMed ID: 36455273
[TBL] [Abstract][Full Text] [Related]
17. Development of a degrader against oncogenic fusion protein FGFR3-TACC3.
Shibata N; Cho N; Koyama H; Naito M
Bioorg Med Chem Lett; 2022 Mar; 60():128584. PubMed ID: 35085722
[TBL] [Abstract][Full Text] [Related]
18. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.
Daly C; Castanaro C; Zhang W; Zhang Q; Wei Y; Ni M; Young TM; Zhang L; Burova E; Thurston G
Oncogene; 2017 Jan; 36(4):471-481. PubMed ID: 27345413
[TBL] [Abstract][Full Text] [Related]
19. FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium.
Best SA; Harapas CR; Kersbergen A; Rathi V; Asselin-Labat ML; Sutherland KD
Oncogene; 2018 Nov; 37(46):6096-6104. PubMed ID: 29991799
[TBL] [Abstract][Full Text] [Related]
20. Unique signalling connectivity of FGFR3-TACC3 oncoprotein revealed by quantitative phosphoproteomics and differential network analysis.
Lombardi B; Ashford P; Moya-Garcia AA; Rust A; Crawford M; Williams SV; Knowles MA; Katan M; Orengo C; Godovac-Zimmermann J
Oncotarget; 2017 Nov; 8(61):102898-102911. PubMed ID: 29262532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]